Cholangiocarcinoma (CCA)

PAGE CONTENTS

Several factors are known to increase the risk of developing cholangiocarcinoma (CCA).1 These include diseases of the liver and bile ducts, and diseases affecting the digestive and endocrine systems. Lifestyle choices are less evident risk factors but have also been attracting attention as potential triggers for CCA development. Host genetic polymorphisms also have an important role in carcinogenesis.1

Even though studies show multiple established risk factors for CCA, it is not always possible to identify any of these in most patients.2 Additionally, the same risk factor may have a different impact on the development of intrahepatic (iCCA) and extrahepatic (eCCA) tumors.3

Primary Sclerosing Cholangitis

Primary sclerosing cholangitis (PSC) is an autoimmune disease that leads to inflammation, proliferation of the biliary epithelial cells, obstruction of the bile ducts and to the production of endogenous bile mutagens.3 The risk of PSC patients in developing CCA is augmented 400-fold,4 however, only up to 10% of CCA cases have been correlated with the presence of PSC.5

Bile Duct Cysts

Bile duct cysts are a congenital disorder that result from a defect in the pancreatic-biliary junction. This defect promotes the reflux of pancreatic enzymes that go into the biliary system leading to inflammation and to a dilatation of the biliary tree.6 Cysts can be divided into 5 types, with types I (solitary extrahepatic cyst) and IV (extrahepatic and intrahepatic cyst) having the highest CCA incidence.7 

Patients with bile duct cysts have been reported to develop CCA at an average age of 32, which is a younger age than the normal onset age of presentation.7,8 

Hepatolithiasis, Cholelithiasis and Choledocholithiasis

The presence of calculi in the biliary tree, hepatolithiasis, is common in East Asia and rare in Western countries.9 Patients with hepatolithiasis show an incidence of iCCA up to 13%.9,10 These calculi lead to chronic inflammation, bile stasis and to bacterial infections, which may be related to CCA development.9

Cirrhosis and Viral Hepatitis

Cirrhosis has been identified as a risk factor for developing iCCA and eCCA.11,12 In this condition, pro-inflammatory cytokines are released, cellular proliferation is enhanced, and the liver parenchyma turns fibrotic. Liver function is also compromised.13

Epidemiological studies point also to the role of Hepatitis B (HBV) and C (HCV) virus infection in CCA development.14 CCA incidence once patients are infected is different when comparing Western and Asian countries.11,15,16 Different studies show a strong association of iCCA to HBV.16,17 In HBV and HCV infections, cirrhosis occurs but there is also a carcinogenic effect of the virus at the cellular level. Cellular proliferation resulting from liver inflammation occurs, which in turn predisposes cells to malignancy.18

Inflammatory Bowel Disease

There are studies relating inflammatory bowel disease (IBD) with the risk of CCA development.19,20 Ulcerative colitis and Crohn’s disease induce chronic inflammation and microbiome changes that may set conditions for tumor formation.21

Chronic Pancreatitis and Duodenal/Gastric Ulcer

Chronic pancreatitis and ulcers of the digestive system associated with Helicobacter Pylori (H. Pylori) infection have been related to increased risk of CCA development.22 Pancreatitis causes biliary stricture resulting in cholangitis and cholelithiasis, which promote tumorigenesis.23 H. Pylori is responsible for increased cellular kinetics of the biliary system and for leading to the formation of stones.24

Parasitic Infections

Parasitic infections caused by Opisthorchis viverrini and Clonorchis sinensis liver flukes are important risk factors in CCA. These worms colonize the bile ducts and may infest humans via ingestion of raw or undercooked fish.1 In Eastern Asia, CCA is mainly associated with these infections, as the relevant parasites are endemic in the region.25 Estimates point that up to 10% of infected individuals will develop CCA.26 The parasites lead to chronic inflammation, cholangitis and fibrosis,27 and multiple infections can promote carcinogenesis.28,29 Cholangiocytes are also more susceptible to the impact of carcinogens.30 

Type 2 Diabetes and Obesity

In type 2 diabetic patients, a compensatory hyperinsulinemia is observed, and insulin has potential to induce malignant growth.31 Studies have shown an association between type 2 diabetes and CCA, particularly with iCCA.22 This association may be also mediated by other conditions such as obesity. However, data on this subject is  limited.12

Tobacco Smoking and Alcohol Consumption

Heavy consumption of alcohol can be a risk factor for CCA.3 Alcohol induces CYP2E1 with consequent increase in reactive oxygen-species, lipid peroxidation and DNA damage.32 The mechanism that leads to carcinogenesis is, however, not clear. 

Data on tobacco smoking and its impact on CCA is also not consistent.11 There are, however, carcinogenic components that are metabolized by hepatic microsomes and further excreted to bile that might contribute to carcinogenesis.33

Toxins

The radiographic contrast agent Thorotrast that was used between 1930 and 1960 is associated with the development of CCA.34 Patients show a 300-fold increase in CCA risk after contact with Thorotrast.35 There is also a lag time of 16 to 45 years between exposure and tumor formation due to the lifetime of the contrast agent.34

Exposure to asbestos can also contribute to increasing the risk of CCA formation.36

Genetic Polymorphisms

Gene polymorphisms have been related to both increased and decreased risk of CCA, whether there are or not environmental factors associated.1 Polymorphism of genes that encode for enzymes that have a role in DNA repair or de immune response may lead to CCA development. Few of the polymorphisms that have been observed occur in genes coding for glutathione 5-transferases (GSTs), in carcinogen detoxification enzymes GSTM1 and GSTT1 and in oxoguanine glycosylase 1.37,38

References

  1. Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 2019 May;39 Suppl 1:19-31. doi:10.1111/liv.14095
  2. Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology. 2008 Jul;48(1):308-21. doi: 10.1002/hep.22310
  3. Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology. 2011 Jul;54(1):173-84. doi: 10.1002/hep.24351.
  4. Boonstra K, Weersma RK, van Erpecum KJ, et al.  Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013 Dec;58(6):2045-55. doi:10.1002/hep.26565
  5. LaRusso NF, Shneider BL, Black D, et al. Primary sclerosing cholangitis: summary of a workshop. Hepatology. 2006 Sep;44(3):746-64. doi: 10.1002/hep.21337
  6. Kamisawa T, Egawa N, Nakajima H, Tsuruta K, Okamoto A, Matsukawa M. Origin of the long common channel based on pancreatographic findings in pancreaticobiliary maljunction. Dig Liver Dis. 2005 May;37(5):363-7. doi: 10.1016/j.dld.2004.11.007
  7. Söreide K, Körner H, Havnen J, Söreide JA. Bile duct cysts in adults. Br J Surg. 2004 Dec;91(12):1538-48. doi:10.1002/bjs.4815
  8. Todani T, Watanabe Y, Toki A, Urushihara N. Carcinoma related to choledochal cysts with internal drainage operations. Surg Gynecol Obstet. 1987 Jan;164(1):61-4. 
  9. Kim HJ, Kim JS, Joo MK, et al. Hepatolithiasis and intrahepatic cholangiocarcinoma: a review. World J Gastroenterol. 2015 Dec 28;21(48):13418-31. doi:10.3748/wjg.v21.i48.13418
  10. Lin CC, Lin PY, Chen YL. Comparison of concomitant and subsequent cholangiocarcinomas associated with hepatolithiasis: clinical implications. World J Gastroenterol. 2013 Jan 21;19(3):375-80. doi:10.3748/wjg.v19.i3.375
  11. Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? a meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol. 2012 Jul;57(1):69-76. doi: 10.1016/j.jhep.2012.02.022 
  12.  Welzel TM, Graubard BI, El-Serag HB, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the united states: a population-based case-control study. Clin Gastroenterol Hepatol. 2007 Oct;5(10):1221-8. doi: 10.1016/j.cgh.2007.05.020
  13. Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014 Jun 21;383(9935):2168-79. doi:10.1016/S0140-6736(13)61903-0
  14. Matsumoto K, Onoyama T, Kawata S, et al. Hepatitis B and C virus infection is a risk factor for the development of cholangiocarcinoma. Intern Med. 2014;53(7):651-4. doi:10.2169/internalmedicine.53.1410
  15. El-Serag HB, Engels EA, Landgren O, et al. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of US veterans. Hepatology. 2009 Jan;49(1):116-23. doi:10.1002/hep.22606
  16. Zhou Y, Zhao Y, Li B, et al. Hepatitis viruses infection and risk of intrahepatic cholangiocarcinoma: evidence from a meta-analysis. BMC Cancer. 2012 Jul 16;12:289. doi:10.1186/1471-2407-12-289
  17. Li M, Li J, Li P, et al. Hepatitis B virus infection increases the risk of cholangiocarcinoma: a meta-analysis and systematic review. J Gastroenterol Hepatol. 2012 Oct;27(10):1561-8. doi: 10.1111/j.1440-1746.2012.07207.x
  18. Allen KJ, Gurrin LC, Constantine CC, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med. 2008 Jan 17;358(3):221-30. doi: 10.1056/NEJMoa073286
  19. Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the united states: a case-control study. Gastroenterology. 2005 Mar;128(3):620-6. doi:10.1053/j.gastro.2004.12.048
  20. Welzel TM, Mellemkjaer L, Gloria G, et al. Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study. Int J Cancer. 2007 Feb 1;120(3):638-41. doi: 10.1002/ijc.22283
  21. Holmes E, Li JV, Athanasiou T, Ashrafian H, Nicholson JK. Understanding the role of gut microbiome-host metabolic signal disruption in health and disease. Trends Microbiol. 2011 Jul;19(7):349-59. doi:10.1016/j.tim.2011.05.006 
  22. Petrick JL, Yang B, Altekruse SF, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the united states: a population-based study in SEER-medicare. PLoS One. 2017 Oct 19;12(10):e0186643. doi: 10.1371/journal.pone.0186643
  23. Vijungco JD, Prinz RA. Management of biliary and duodenal complications of chronic pancreatitis. World J Surg. 2003 Nov;27(11):1258-70. doi:10.007/s00268-003-7246-7
  24. Kuroki T, Fukuda K, Yamanouchi K, et al. Helicobacter pylori accelerates the biliary epithelial cell proliferation activity in hepatolithiasis. Hepatogastroenterology. 2002 May-Jun;49(45):648-51
  25. Sripa B, Kaewkes S, Sithithaworn P, et al. Liver fluke induces cholangiocarcinoma. PLoS Med. 2007 Jul;4(7):e201. doi: 10.1371/journal.pmed.0040201
  26. Dodson RM, Weiss MJ, Cosgrove D, et al. Intrahepatic cholangiocarcinoma: management options and emerging therapies. J Am Coll Surg. 2013 Oct;217(4):736-750.e4. doi:10.1016/j.jamcollsurg.2013.05.021
  27. Sithithaworn P, Yongvanit P, Duenngai K, Kiatsopit N, Pairojkul C. Roles of liver fluke infection as risk factor for cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2014 May;21(5):301-8. doi:10.1002/jhbp.62
  28. Honjo S, Srivatanakul P, Sriplung H, et al. Genetic and environmental determinants of risk for cholangiocarcinoma via opisthorchis viverrini in a densely infested area in nakhon phanom, northeast thailand. Int J Cancer. 2005 Dec 10;117(5):854-60. doi:10.1002/ijc.21146. Erratum in: Int J Cancer. 2005 Dec 20;117(6):1066
  29. Sripa B, Deenonpoe R, Brindley PJ. Co-infections with liver fluke and Helicobacter species: a paradigm change in pathogenesis of opisthorchiasis and cholangiocarcinoma? Parasitol Int. 2017 Aug;66(4):383-389. doi: 10.1016/j.parint.2016.11.016
  30. Kaewpitoon N, Kaewpitoon SJ, Pengsaa P, Sripa B. Opisthorchis viverrini: the carcinogenic human liver fluke. World J Gastroenterol. 2008 Feb 7;14(5):666-74. doi:10.3748/wjg.14.666
  31. Jing W, Jin G, Zhou X, et al. Diabetes mellitus and increased risk of cholangiocarcinoma: a meta-analysis. Eur J Cancer Prev. 2012 Jan;21(1):24-31. doi:10.1097/CEJ.0b013e3283481d89
  32. Zakhari S. Overview: how is alcohol metabolized by the body? alcohol res health. 2006;29(4):245-54. 
  33. Staretz ME, Murphy SE, Patten CJ, Nunes MG, Koehl W, Amin S et al. Comparative metabolism of the tobacco-related carcinogens benzo[a]pyrene, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, and N’- nitrosonornicotine in human hepatic microsomes. Drug Metab Dispos. 1997 Feb;25(2):154-62
  34. Lipshutz GS, Brennan TV, Warren RS. Thorotrast-induced liver neoplasia: a collective review. J Am Coll Surg. 2002 Nov;195(5):713-8. doi: 10.1016/s1072-7515(02)01287-5
  35. Ishikawa Y, Wada I, Fukumoto M. Alpha-particle carcinogenesis in thorotrast patients: epidemiology, dosimetry, pathology, and molecular analysis. J Environ Pathol Toxicol Oncol. 2001;20(4):311-5
  36. Brandi G, Di Girolamo S, Farioli A, de Rosa F, Curti S, Pinna AD et al. Asbestos: a hidden player behind the cholangiocarcinoma increase? findings from a case-control analysis. Cancer Causes Control. 2013 May;24(5):911-8. doi:10.1007/s10552-013-0167-3 
  37. Marahatta SB, Punyarit P, Bhudisawasdi V, Paupairoj A, Wongkham S, Petmitr S. Polymorphism of glutathione S-transferase omega gene and risk of cancer. Cancer Lett. 2006 May 18;236(2):276-81. doi: 10.1016/j.canlet.2005.05.020
  38. You SH, Wang X, Huang S, Wang M, Ji GZ, Xia JR et al. MYH rs3219476 and rs3219472 polymorphisms and risk of cholangiocarcinoma. Mol Med Rep. 2013 Jan;7(1):347-51. doi:10.3892/mmr.2012.1175

Reviewed by Kyle Habet, MD, on 7/1/2021.

READ MORE ON CCA